1-(8-(dimethylamino)-8-phenyl-2-azaspiro[4.5]decan-2-yl)butan-1-one

ID: ALA4463703

PubChem CID: 118662309

Max Phase: Preclinical

Molecular Formula: C21H32N2O

Molecular Weight: 328.50

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCCC(=O)N1CCC2(CCC(c3ccccc3)(N(C)C)CC2)C1

Standard InChI: InChI=1S/C21H32N2O/c1-4-8-19(24)23-16-15-20(17-23)11-13-21(14-12-20,22(2)3)18-9-6-5-7-10-18/h5-7,9-10H,4,8,11-17H2,1-3H3

Standard InChI Key: XEFUCVUEFXVJSU-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   11.6759  -13.8592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0804  -14.5650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8893  -14.5676    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2999  -13.8661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8955  -13.1603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0804  -13.1561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1314  -13.2429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3763  -13.5701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4542  -14.3895    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.2575  -14.5685    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8757  -13.2814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.6667  -13.4869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6582  -12.4937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8757  -14.4412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6627  -15.2277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2377  -15.8025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0246  -15.5916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2333  -14.8007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6568  -14.2293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8415  -14.9303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0669  -14.6701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0035  -15.7312    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.4542  -15.2109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6795  -14.9507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  6  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  1  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10  1  1  0
  4 11  1  0
 11 12  1  0
 11 13  1  0
  4 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 14  1  0
  9 20  1  0
 20 21  1  0
 20 22  2  0
 21 23  1  0
 23 24  1  0
M  END

Associated Targets(Human)

OPRL1 Tchem Nociceptin receptor (3823 Activities)

Discover Target: OPRL1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRM1 Tclin Mu opioid receptor (19785 Activities)

Discover Target: OPRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 328.50	Molecular Weight (Monoisotopic): 328.2515	AlogP: 4.04	#Rotatable Bonds: 4
Polar Surface Area: 23.55	Molecular Species: BASE	HBA: 2	HBD: ┄
#RO5 Violations: ┄	HBA (Lipinski): 3	HBD (Lipinski): ┄	#RO5 Violations (Lipinski): ┄
CX Acidic pKa: ┄	CX Basic pKa: 9.93	CX LogP: 3.55	CX LogD: 1.07
Aromatic Rings: 1	Heavy Atoms: 24	QED Weighted: 0.83	Np Likeness Score: -0.53

References

1. Rosse G.. (2016) Treatment of Pain with Spirocylic Cyclohexane Derivatives Having Dual Specificity for ORL-1 and μ-Opioid Receptors., 7 (9): [PMID:27660683] [10.1021/acsmedchemlett.6b00277]
2. Ghirmai, Senait; Azar, Marc R and Cashman, John R. 2009-09-15 Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. [PMID:19683449]
3. Toll, Lawrence L and 5 more authors. 2009-12 Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. [PMID:19773529]
4. McLeod, Robbie L and 20 more authors. 2010-03-25 Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. [PMID:20006596]
5. Pike, Victor W and 14 more authors. 2011-04-28 Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. [PMID:21438532]
6. Cami-Kobeci, Gerta; Polgar, Willma E; Khroyan, Taline V; Toll, Lawrence and Husbands, Stephen M. 2011-10-13 Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. [PMID:21866885]
7. Zaveri, Nurulain T; Jiang, Faming; Olsen, Cris; Polgar, Willma E and Toll, Lawrence. 2013-06-01 Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I. [PMID:23623415]
8. Journigan, V Blair VB, Polgar, Willma E WE, Khroyan, Taline V TV and Zaveri, Nurulain T NT. 2014-04-15 Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. [PMID:24657054]
9. Linz, Klaus K and 13 more authors. 2014-06 Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. [PMID:24713140]
10. Kumar, Vinod and 10 more authors. 2014-05-22 Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity. [PMID:24761755]
11. Cueva, Juan Pablo and 8 more authors. 2015-05-28 C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. [PMID:25898137]
12. and Zaveri, Nurulain T NT. 2016-08-11 Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. [PMID:26878436]
13. Guillemyn, Karel and 18 more authors. 2016-04-28 Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. [PMID:27035422]
14. Arcuri, Ludovico L and 12 more authors. 2018-03 Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. [PMID:29232769]
15. Gege, Christian and 15 more authors. 2018-05-15 Identification and biological evaluation of thiazole-based inverse agonists of RORγt. [PMID:29631962]
16. Kamakolanu, Uma Gayathri and 9 more authors. 2020-03-12 Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models. [PMID:31951130]

1-(8-(dimethylamino)-8-phenyl-2-azaspiro[4.5]decan-2-yl)butan-1-one

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Associated Targets(non-human)

Molecule Features

Drug Indications

Mechanisms of Action

Calculated Properties

References

Source